Načítá se...
Targeting CD73 in the tumor microenvironment with MEDI9447
MEDI9447 is a human monoclonal antibody that is specific for the ectoenzyme CD73 and currently undergoing Phase I clinical trials. Here we show that MEDI9447 is a potent inhibitor of CD73 ectonucleotidase activity, with wide ranging immune regulatory consequences. MEDI9447 results in relief from ade...
Uloženo v:
Vydáno v: | Oncoimmunology |
---|---|
Hlavní autoři: | , , , , , , , , , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
Taylor & Francis
2016
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5007986/ https://ncbi.nlm.nih.gov/pubmed/27622077 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1208875 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|